Table 2

Primary treatment choice and response to treatment in type 1 retinopathy of prematurity (ROP)

ParameterBevacizumab injection
(37 eyes)
Ranibizumab injection
(60 eyes)
Laser ablation
(32 eyes)
Combination therapy
(2 eyes)
ROP zone at primary treatment, eyes
 Zone I6 eyes10 eyes2 eyesNone
 Posterior zone II10 eyes21 eyes3 eyesNone
 Zone II21 eyes29 eyes27 eyes2 eyes
PMA at primary treatment, weeks38.4±4.236.3±2.843.5±14.137.5
Anti-VEGF injection dose and numbers
B 0.625 mg 9 eyesR 0.2 mg 48 eyesnoneB 0.5 mg 1 eye
B 0.5 mg 12 eyesR 0.1 mg 12 eyesnoneB 0.25 mg 1 eye
B 0.325 mg 6 eyesnone
B 0.2 mg 10 eyesnone
Periods of plus disease disappearance after primary treatment, days11.6±8.414.7±14.5 ~ not disappear34.1±26.214
Additional treatment-requiring eyes10 eyes (27.03%)25 eyes (41.67%)NoneNone
Duration of additional treatment after primary treatment, days38.6±9.871.8±38.0
  • Values of gestational age, birth weight, PMA at primary treatment, periods of plus disease disappearance and duration of additional treatment in each subgroup are presented as mean±SD.

  • anti-VEGF, antivascular endothelial growth factor.B, bevacizumab; PMA, postmenstrual age; R, ranibizumab;